MedAlliance

MedAlliance is a privately owned company dedicated to developing ground-breaking technology for the treatment of coronary and peripheral arterial disease.
Using breakthrough proprietary technology that combines the proven safety and efficacy of sirolimus with advanced MicroReservoir and Cell Adherent Technology (CAT™).
MedAlliance has found a unique solution to the challenge of controlled and sustained sirolimus release with their SELUTION SLR™ Technology.

www.medalliance.com

Follow

Subscribe to Wondr Medical

Why sustained release matters?

Watch Now

CAT™ balloon coating technology – 3 step mechanism of action

Watch Now

PRESTIGE Study - 12 month results with the SELUTION Sirolimus Coated Balloon in TASC C and D tibial occlusive disease.

Watch Now

Subscribe for updates from MedAlliance as well as breaking news and case discussion from Wondr.

Browse by Topic

MedAlliance

Why sustained release matters?

CAT™ balloon coating technology – 3 step mechanism of action

PRESTIGE Study - 12 month results with the SELUTION Sirolimus Coated Balloon in TASC C and D tibial occlusive disease.

An Italian Perspective on latest generation sirolimus DEBs + Clinical Case

SELUTION SLR – Addressing unmet clinical needs

SELUTION SLR – Cell Adherent Technology (CAT™)

SELUTION SLR – Why sirolimus could offer clinical benefits over paclitaxel?

SELUTION SLR – MicroReservoir Technology

SELUTION SLR - Breakthrough Technology

SELUTION SLR – Sustained Limus Release

SELUTION SLR – First-in Human Clinical Data and Clinical Experience

Add to calendar

Rutherford Medicine is now Wondr Medical